Sandoz Group Past Earnings Performance
Past criteria checks 0/6
Sandoz Group's earnings have been declining at an average annual rate of -43.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 5.8% per year.
Key information
-43.8%
Earnings growth rate
-101.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 5.8% |
| Return on equity | -0.06% |
| Net Margin | -0.08% |
| Next Earnings Update | 05 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sandoz Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 10,111 | -8 | 2,476 | 968 |
| 31 Mar 24 | 10,045 | 35 | 2,433 | 947 |
| 31 Dec 23 | 9,979 | 77 | 2,389 | 926 |
| 30 Sep 23 | 9,770 | 345 | 2,315 | 899 |
| 30 Jun 23 | 9,561 | 613 | 2,241 | 871 |
| 31 Mar 23 | 9,434 | 731 | 2,184 | 852 |
| 31 Dec 22 | 9,306 | 848 | 2,127 | 833 |
| 31 Dec 21 | 9,678 | 908 | 2,127 | 911 |
| 31 Dec 20 | 9,658 | 462 | 2,132 | 873 |
Quality Earnings: SDZN.Y is currently unprofitable.
Growing Profit Margin: SDZN.Y is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SDZN.Y is unprofitable, and losses have increased over the past 5 years at a rate of 43.8% per year.
Accelerating Growth: Unable to compare SDZN.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SDZN.Y is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: SDZN.Y has a negative Return on Equity (-0.06%), as it is currently unprofitable.